Tillkännagivande • May 18
MPS Pharmaa Limited to Report Q4, 2026 Results on May 28, 2026 MPS Pharmaa Limited announced that they will report Q4, 2026 results on May 28, 2026 Tillkännagivande • Jan 22
MPS Pharmaa Limited to Report Q3, 2026 Results on Feb 02, 2026 MPS Pharmaa Limited announced that they will report Q3, 2026 results on Feb 02, 2026 Tillkännagivande • Nov 04
MPS Pharmaa Limited to Report Q2, 2026 Results on Nov 14, 2025 MPS Pharmaa Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Tillkännagivande • Sep 03
MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025 MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025, at 09:30 Indian Standard Time. Location: 138, roz-ka-meo industrial area, sohna, distt, mewat- 122103, haryana, India Tillkännagivande • Aug 02
MPS Pharmaa Limited to Report Q1, 2026 Results on Aug 12, 2025 MPS Pharmaa Limited announced that they will report Q1, 2026 results on Aug 12, 2025 Tillkännagivande • May 19
MPS Pharmaa Limited to Report Q4, 2025 Results on May 28, 2025 MPS Pharmaa Limited announced that they will report Q4, 2025 results on May 28, 2025 Tillkännagivande • Oct 31
MPS Pharmaa Limited to Report Q2, 2025 Results on Nov 14, 2024 MPS Pharmaa Limited announced that they will report Q2, 2025 results on Nov 14, 2024 Tillkännagivande • Sep 03
MPS Pharmaa Limited, Annual General Meeting, Sep 28, 2024 MPS Pharmaa Limited, Annual General Meeting, Sep 28, 2024, at 09:30 Indian Standard Time. Location: 138, roz-ka-meo industrial area, sohna, distt, mewat- 122103, haryana, India Tillkännagivande • Jul 30
MPS Pharmaa Limited to Report Q1, 2025 Results on Aug 13, 2024 MPS Pharmaa Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Tillkännagivande • May 16
MPS Pharmaa Limited to Report Q4, 2024 Results on May 30, 2024 MPS Pharmaa Limited announced that they will report Q4, 2024 results on May 30, 2024 Tillkännagivande • Oct 31
MPS Pharmaa Limited to Report Q2, 2023 Results on Nov 09, 2023 MPS Pharmaa Limited announced that they will report Q2, 2023 results on Nov 09, 2023 Tillkännagivande • Aug 30
MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2023 MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2023, at 09:30 Indian Standard Time. Tillkännagivande • Aug 03
MPS Pharmaa Limited to Report Q1, 2024 Results on Aug 12, 2023 MPS Pharmaa Limited announced that they will report Q1, 2024 results at 3:30 PM, Indian Standard Time on Aug 12, 2023 Tillkännagivande • Jul 06
MPS Pharmaa Limited Announces Resignation of Manoj Kumar Jain from the Position of the Independent Director of the Company with Immediate Effect MPS Pharmaa Limited announced that the company has received on 05th July, 2023, a resignation letter dated 04th July, 2023 from Mr. Manoj Kumar Jain, Independent Director of the Company wherein he has tendered his resignation from the position of the Independent Director of the Company with immediate effect. Resignation due to personal reasons commitments and business commitments. Mr. Manoj Kumar Jain has been associated with the company since 26-12-2013. Board Change • Jun 26
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • May 17
MPS Pharmaa Limited to Report Q4, 2023 Results on May 29, 2023 MPS Pharmaa Limited announced that they will report Q4, 2023 results on May 29, 2023 Board Change • Mar 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Feb 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Feb 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jan 24
MPS Pharmaa Limited to Report Q3, 2023 Results on Feb 03, 2023 MPS Pharmaa Limited announced that they will report Q3, 2023 results on Feb 03, 2023 Board Change • Jan 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jan 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Nov 03
Advik Laboratories Limited to Report Q2, 2023 Results on Nov 12, 2022 Advik Laboratories Limited announced that they will report Q2, 2023 results on Nov 12, 2022 Board Change • Oct 31
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 10
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 19
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Sep 02
Advik Laboratories Limited, Annual General Meeting, Sep 29, 2022 Advik Laboratories Limited, Annual General Meeting, Sep 29, 2022, at 09:30 Indian Standard Time. Location: 138, Roz- Ka - Meo Industrial Area, Sohna, Distt. Mewat-122 103, Haryana Sohna India Board Change • Sep 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 16
First quarter 2023 earnings released: ₹0.11 loss per share (vs ₹0.15 loss in 1Q 2022) First quarter 2023 results: ₹0.11 loss per share (up from ₹0.15 loss in 1Q 2022). Net loss: ₹2.03m (loss narrowed 27% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Tillkännagivande • Jul 31
Advik Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022 Advik Laboratories Limited announced that they will report Q1, 2023 results on Aug 12, 2022 Tillkännagivande • Apr 16
Advik Laboratories Limited announced that it expects to receive INR 62.5 million in funding from Neelabh Spinning Mills Pvt. Ltd., Omkam Securities Private Limited, Dhiru Builders and Promoters Private Limited and other investors Advik Laboratories Limited announced a private placement of up to 25,000,000 pre-paid warrants at a price of INR 2.5 per warrant for gross proceeds of up to INR 62,500,000 on April 15, 2022. The transaction will include participation from promoters Aditya Aggarwal, Seema Aggarwal, and Omkam Securities Private Limited, and non-promoters Neelabh Spinning Mills Pvt. Ltd., and returning investor Dhiru Builders and Promoters Private Limited. The total issue price of warrants is INR 10, of which the company will receive 25% as upfront payment at the time of allotment of warrants and the remaining 75% will be paid upon exercise of warrants. Each warrant is exercisable to acquire 1 common share of the company, at an exercise price of INR 7.5 per share for a period of 18 months from the date of closing. The company will issue securities on preferential basis. The transaction has been approved by the board of directors of the company, and is subject to approval from company's shareholders at its extraordinary general meeting scheduled to be held on May 18, 2022, and approval from applicable regulatory authorities. Reported Earnings • Jul 06
Full year 2021 earnings released: ₹2.31 loss per share (vs ₹0.61 loss in FY 2020) Full year 2021 results: Net loss: ₹44.2m (loss widened 279% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings. 
